firstly, the patient cohort in open studies and in clinic experience, at the time of rituximab treatment, had moderate to severe disease activity and most had failed conventional immunosuppressants. in contrast patients participating in the two dbrcts had active disease, but patients who had failed conventional therapy were excluded.